Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Colorectal Neoplasms 112Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 85Glioblastoma 72Ovarian Neoplasms 62Brain Neoplasms 45Lung Neoplasms 41Glioma 41Fallopian Tube Neoplasms 41Neoplasms 38Colonic Neoplasms 34Gliosarcoma 33Carcinoma, Renal Cell 32Rectal Neoplasms 31Neoplasm Metastasis 29Pancreatic Neoplasms 19Carcinoma, Hepatocellular 19Melanoma 18Adenocarcinoma of Lung 18Astrocytoma 15Kidney Neoplasms 13Stomach Neoplasms 12Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Oligodendroglioma 11Liver Neoplasms 11Esophageal Neoplasms 11Sarcoma 10Adenocarcinoma, Bronchiolo-Alveolar 10Central Nervous System Neoplasms 9

Interventions

Carboplatin 23Cisplatin 19pembrolizumab 14Paclitaxel 12Gemcitabine 12Pemetrexed 11130-nm albumin-bound paclitaxel 9Everolimus 8Cetuximab 8Fluorouracil 7Axitinib 6osimertinib 5durvalumab 5Sunitinib 5Radiotherapy 5Erlotinib Hydrochloride 5Docetaxel 5Cyclophosphamide 5Albumin-Bound Paclitaxel 5Sorafenib 4Radiation 4Nivolumab 4Ipilimumab 4vosaroxin 3Radiotherapy, Intensity-Modulated 3Octreotide 3Irinotecan 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3pralsetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Carcinoma × Bevacizumab × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

NCT00737243 2016-08-17

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
289 enrolled 5 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡